ReviewJournal of clinical medicine2025
Serum Biomarkers in Acute Ischemic Stroke: Clinical Applications and Emerging Insights.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- An umbrella review of systematic reviews and meta-analyses evaluating the efficacy and safety of mechanical thrombectomy for acute ischemic stroke.Annals of medicine and surgery (2012) · 2026Article
- Serum Endocan as a Novel Biomarker of Cerebral Ischemia-Reperfusion Injury in a Rat Model.Biomedicines · 2026Article
- Copeptin in acute ischemic stroke: a surrogate marker of AVP-system activation with temporal dynamics and clinical implications.Journal of thrombosis and thrombolysis · 2026Review
- High-specificity identification of large vessel occlusion stroke using D-dimer and NT-proBNP combined with clinical variables.Frontiers in neurology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute ischemic stroke (AIS) remains a major cause of long-term disability and death worldwide, posing significant challenges to healthcare systems. Timely diagnosis is crucial, as acute phase therapeutic options are highly time-sensitive and most effective when administered early in the disease course. In this context, serum biomarkers have emerged as a promising and complementary tool to aid in the rapid and accurate diagnosis, prognosis, and therapeutic monitoring of AIS. This narrative review aims to provide a comprehensive overview of the current landscape of serum biomarkers relevant to AIS. These biomarkers are categorized based on the underlying pathophysiological mechanisms they reflect, including markers of inflammation and oxidative stress, neuronal and endothelial injury, and those related to hemostasis and fibrinolysis. Their biological significance is evaluated through the spectrum of their diagnostic sensitivity and specificity and their potential integration into clinical practice. In addition, many of these biomarkers offer prognostic insights, helping to predict the likelihood of complications, recurrent stroke, or poor functional recovery. Furthermore, their role as a potential tool for the differential diagnosis of patients presenting with minor or nonspecific neurological symptoms and therapeutic monitoring is emphasized. Despite the promising potential of these biomarkers, their translation into routine clinical use remains limited.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.